Unknown

Dataset Information

0

A rapid Orthopoxvirus purification protocol suitable for high-containment laboratories.


ABSTRACT: Virus purification in a high-containment setting provides unique challenges due to barrier precautions and operational safety approaches that are not necessary in lower biosafety level (BSL) 2 environments. The need for high risk group pathogen diagnostic assay development, anti-viral research, pathogenesis and vaccine efficacy research necessitates work in BSL-3 and BSL-4 labs with infectious agents. When this work is performed in accordance with BSL-4 practices, modifications are often required in standard protocols. Classical virus purification techniques are difficult to execute in a BSL-3 or BSL-4 laboratory because of the work practices used in these environments. Orthopoxviruses are a family of viruses that, in some cases, requires work in a high-containment laboratory and due to size do not lend themselves to simpler purification methods. Current CDC purification techniques of orthopoxviruses uses 1,1,2-trichlorotrifluoroethane, commonly known as Genetron®. Genetron® is a chlorofluorocarbon (CFC) that has been shown to be detrimental to the ozone and has been phased out and the limited amount of product makes it no longer a feasible option for poxvirus purification purposes. Here we demonstrate a new Orthopoxvirus purification method that is suitable for high-containment laboratories and produces virus that is not only comparable to previous purification methods, but improves on purity and yield.

SUBMITTER: Hughes L 

PROVIDER: S-EPMC9533856 | biostudies-literature | 2017 May

REPOSITORIES: biostudies-literature

altmetric image

Publications

A rapid Orthopoxvirus purification protocol suitable for high-containment laboratories.

Hughes Laura L   Wilkins Kimberly K   Goldsmith Cynthia S CS   Smith Scott S   Hudson Paul P   Patel Nishi N   Karem Kevin K   Damon Inger I   Li Yu Y   Olson Victoria A VA   Satheshkumar P S PS  

Journal of virological methods 20170126


Virus purification in a high-containment setting provides unique challenges due to barrier precautions and operational safety approaches that are not necessary in lower biosafety level (BSL) 2 environments. The need for high risk group pathogen diagnostic assay development, anti-viral research, pathogenesis and vaccine efficacy research necessitates work in BSL-3 and BSL-4 labs with infectious agents. When this work is performed in accordance with BSL-4 practices, modifications are often require  ...[more]

Similar Datasets

| S-EPMC10407794 | biostudies-literature
| S-EPMC7502897 | biostudies-literature
| S-EPMC2710004 | biostudies-literature
| S-EPMC8414973 | biostudies-literature
| PRJNA286208 | ENA
| S-EPMC10951993 | biostudies-literature
| S-EPMC7547523 | biostudies-literature
| S-EPMC7284835 | biostudies-literature
| S-EPMC7528119 | biostudies-literature
| S-EPMC5521553 | biostudies-literature